Original Publication Date: 14 December, 2013
Publication / Source: Future Oncology
Authors: Elena Verzoni, Filippo de Braud, Francesca Fabiani, Paolo Grassi, Isabella Testa & Giuseppe Procopio
Recent therapeutic advances have changed the treatment landscape of metastatic renal cell carcinoma. Unfortunately, the seven agents now available are not based on biomarkers that would indicate which one could provide the best benefit for every patient. We have reviewed the available information concerning the impact of each treatment on comorbidities or status that are frequently seen before commencing treatment for the advanced disease: elderly and patients with cardiovascular complications, metabolic and endocrinology disorders, and infections, as well as impaired organ function (kidney, liver and heart).